Is Decoy Therapeutics Inc. (DCOY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 66.0% / 30% | 724.3% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 66.0% / 33% | 724.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 7.3% / 33% | 80.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 66.0% / 33% | 724.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 7.3% / 33% | 80.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -139.6% | |
| Return on Assets (ROA) | -69.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Total Debt | $221,866 |
| Current Ratio | 3.3 |
| Total Assets | $3M |
Price & Trading
| Last Close | $7.03 |
| 50-Day MA | $8.51 |
| 200-Day MA | $51.32 |
| Avg Volume | 195K |
| Beta | 0.3 |
|
52-Week Range
$6.18
| |
About Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Decoy Therapeutics Inc. (DCOY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Decoy Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Decoy Therapeutics Inc.'s debt ratio?
Decoy Therapeutics Inc.'s debt ratio is 66.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.3%.
What are Decoy Therapeutics Inc.'s key financial metrics?
Decoy Therapeutics Inc. has a market capitalization of $3M. Return on equity stands at -139.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.